Chemoimmunotherapy or chemoradiotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests giving chemotherapy with immunotherapy, or chemotherapy with radiation, before surgery for esophageal cancer. The goal is to see which approach is better at shrinking the tumor and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma (a type of cancer of the esophagus).
- The cancer must be considered removable with surgery.
- Your PET scan must show high FAPI activity in the tumor (a measure of how active the cancer is).
- You must not have received certain types of chemotherapy or immunotherapy before (like platinum drugs, taxanes, 5-FU, or PD-1 inhibitors).
- You must not have serious heart, liver, kidney, or other health conditions that could make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
Hear when a new Resectable Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.